210 related articles for article (PubMed ID: 35405741)
1. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
[TBL] [Abstract][Full Text] [Related]
2. Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1.
Noh JY; Lee IP; Han NR; Kim M; Min YK; Lee SY; Yun SH; Kim SI; Park T; Chung H; Park D; Lee CH
Cell Mol Gastroenterol Hepatol; 2022; 14(4):769-788. PubMed ID: 35843546
[TBL] [Abstract][Full Text] [Related]
3. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment Responsive CD8
Chen Q; Yin H; He J; Xie Y; Wang W; Xu H; Zhang L; Shi C; Yu J; Wu W; Liu L; Pu N; Lou W
Adv Sci (Weinh); 2023 Nov; 10(33):e2302498. PubMed ID: 37867243
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
[TBL] [Abstract][Full Text] [Related]
6. Discovery of AB680: A Potent and Selective Inhibitor of CD73.
Lawson KV; Kalisiak J; Lindsey EA; Newcomb ET; Leleti MR; Debien L; Rosen BR; Miles DH; Sharif EU; Jeffrey JL; Tan JBL; Chen A; Zhao S; Xu G; Fu L; Jin L; Park TW; Berry W; Moschütz S; Scaletti E; Sträter N; Walker NP; Young SW; Walters MJ; Schindler U; Powers JP
J Med Chem; 2020 Oct; 63(20):11448-11468. PubMed ID: 32614585
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract][Full Text] [Related]
8. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
Front Immunol; 2019; 10():925. PubMed ID: 31244820
[TBL] [Abstract][Full Text] [Related]
9. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
11. A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway.
Wurm M; Schaaf O; Reutner K; Ganesan R; Mostböck S; Pelster C; Böttcher J; de Andrade Pereira B; Taubert C; Alt I; Serna G; Auguste A; Stadermann KB; Delic D; Han F; Capdevila J; Nuciforo PG; Kroe-Barrett R; Adam PJ; Vogt AB; Hofmann I
Mol Cancer Ther; 2021 Nov; 20(11):2250-2261. PubMed ID: 34482286
[TBL] [Abstract][Full Text] [Related]
12. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer.
Zhou Q; Ding W; Qian Z; Zhu Q; Sun C; Yu Q; Tai Z; Xu K
Mol Pharm; 2021 Nov; 18(11):4015-4028. PubMed ID: 34648293
[TBL] [Abstract][Full Text] [Related]
14. A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer.
Liu S; Li D; Liu J; Wang H; Horecny I; Shen R; Zhang R; Wu H; Hu Q; Zhao P; Zhang F; Yan Y; Feng J; Zhuang L; Li J; Zhang L; Tao W
Onco Targets Ther; 2021; 14():4561-4574. PubMed ID: 34466002
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
Kaistha BP; Kar G; Dannhorn A; Watkins A; Opoku-Ansah G; Ilieva K; Mullins S; Anderton J; Galvani E; Garcon F; Lapointe JM; Brown L; Hair J; Slidel T; Luheshi N; Ryan K; Hardaker E; Dovedi S; Kumar R; Wilkinson RW; Hammond SA; Eyles J
Cancer Biol Ther; 2024 Dec; 25(1):2296048. PubMed ID: 38206570
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
17. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
18. Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.
Lian W; Jiang D; Lin W; Jiang M; Zhang Y; Wang H; Zhao L
Int J Biol Sci; 2024; 20(1):137-151. PubMed ID: 38164172
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment.
Deng Y; Chen Q; Yang X; Sun Y; Zhang B; Wei W; Deng S; Meng J; Hu Y; Wang Y; Zhang Z; Wen L; Huang F; Wan C; Yang K
Theranostics; 2024; 14(3):1224-1240. PubMed ID: 38323313
[No Abstract] [Full Text] [Related]
20. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
